Hims & Hers Health, Inc. (HIMS) financials
NYSE · Healthcare · Medical - Care Facilities · 2,442 employees · CEO Andrew Dudum
- Price
- $27.68 -6.71%
- Market cap
- $6.23B
- Enterprise value
- $7.16B
- Last report
- Q2 '26 filed 2026-08-10
- Next report
- 2026-11-09 EPS est. $0.06
Revenue (TTM)$2.58B+28.0% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-3.6%-9.8 pp vs a year agoOperating income -$92.7M
Net income (TTM)-$142M-173.4% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$89.9M-24.8% vs a year agoCapex $177M
Diluted EPS (TTM)-$0.63-178.3% vs a year agoSum of the last 4 quarters
Net cash-$705M-803.6% vs a year agoCash + short-term investments - debt
Valuation & key figures
- Market cap
- $6.23B EV $7.16B
- Revenue
- $2.58B Trailing 12 months
- Revenue growth
- +37% FY2026 consensus
- Profit margin
- -5.5% Net income / revenue, TTM
- P/E
- -45.4× Forward -47.0× (FY2026)
- P/S
- 2.4× Price / sales, TTM
- EV / EBITDA
- -93.7× TTM
- Free cash flow
- $89.9M Trailing 12 months
- Net income
- -$142M Trailing 12 months
- Revenue estimate
- $3.21B FY2026 consensus
- Earnings
- 2026-11-09 Revenue est. $893M
- Dividend
- – No dividend
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-08-10): revenue beat by 7.8%, EPS missed by 643.1%Revenue $753M vs $699M expected (+7.8%); EPS -$0.37 vs -$0.05 (-643.1%).
- Revenue growth steady: 38.2% year on yearQ2 '26 revenue $753M, against an average of 38.5% over the four quarters before.
- Operating margin -3.6% (TTM), -9.8 pp on a year agoOperating income grew -173.8% while revenue grew 28.0%.
- Capex 6.9% of revenue (a year ago 7.1%)$177M invested in the last 4 quarters (+24.5% on a year earlier). Free cash flow $89.9M.
- Returned $113M to shareholders = 125.8% of free cash flowBuybacks $113M (a year earlier $35M), dividends $0, stock-based pay $154M (TTM). More than the free cash flow: paid from cash or debt.
- Diluted share count down 9.7% in a year232M diluted shares in Q2 '26, 257M a year earlier.
- Net debt $705MCash + short-term investments $841M, debt incl. leases $1.55B; a year ago net cash $100M.
Last quarter: Q2 '26
Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q2 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $753M | $545M | +38.2% |
| Gross margin | 63.8% | 76.4% | -12.6 pp |
| Operating income | -$97.2M | $26.7M | -463.7% |
| Operating margin | -12.9% | 4.9% | -17.8 pp |
| Net income | -$86.3M | $42.5M | -303.0% |
| Diluted EPS | -$0.37 | $0.17 | -317.6% |
| Operating cash flow | -$35.9M | -$19.1M | -88.0% |
| Capex | $19.4M | $50.3M | -61.4% |
| Free cash flow | -$55.4M | -$69.4M | +20.2% |
| R&D | $0 | $37.8M | -100.0% |
| Stock-based compensation | $42.1M | $35.7M | +17.9% |
Reported vs consensus
2026-08-10| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $753M | $699M | +7.8% |
| EPS (as estimated) | -$0.37 | -$0.05 | -643.1% |
From the report of 2026-08-10 for Q2 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyRevenue by region
share of total| Segment | Q2 '26 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| United States | $622M | – | 82.6% | – | – | |
| Non-US | $131M | – | 17.4% | – | – |
Margins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- $267M
- Capex
- -$177M
- Buybacks
- -$113M
- Dividends
- $0
- Acquisitions
- -$458M
- Net debt issued
- $387M
- Stock-based compensation
- $154M
- Free cash flow
- $89.9M
- Returned to shareholders / FCF
- 125.8%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | -45.4× | 49.3× 2 of 5 years | 41.7× – 57.0× |
| EV / EBITDA | -93.7× | 51.2× 2 of 5 years | 45.9× – 56.4× |
| EV / Sales | 2.8× | 3.1× | 2.0× – 4.3× |
| Price / FCF | 69.3× | 54.9× 3 of 5 years | 26.3× – 98.8× |
| Price / Book | 19.8× | 7.5× | 3.7× – 13.5× |
| FCF yield | 1.4% | 0.3% | -3.2% – 3.8% |
| Return on invested capital | -3.7% | -8.7% | -32.6% – 12.7% |
| Return on equity | -30.0% | -2.0% | -32.2% – 26.4% |
Analysts
Consensus target $32.17 (+16.2%)
range $24.50 – $42.00 · rating Hold
Strong buy0
Buy7
Hold13
Sell0
Strong sell0
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $3.21B | +36.6% | -$0.59 | -215.5% | -47.0× | 8 |
| FY2027 | $4.05B | +26.1% | $0.30 | +150.6% | 92.8× | 9 |
| FY2028 | $4.6B | +13.8% | $0.69 | +131.9% | 40.0× | 7 |
| FY2029 | $4.98B | +8.0% | $0.78 | +13.2% | 35.3× | 2 |
| FY2030 | $4.64B | -6.7% | $0.85 | +8.5% | 32.6× | 4 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Every reported line
All 252 figures Hims & Hers Health, Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).
| Line (SEC label) | Latest quarter | Year ago | y/y | Latest FY | Prior FY | y/y |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $501M | $105M | +377.4% | $143M | $91.2M | +57.1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $32.1M2025-12-31 | $6.1M | +426.2% | $32.1M | $6.1M | +426.2% |
| Accounts Receivable, Allowance for Credit Loss, Current | $02025-12-31 | $0 | – | $0 | $0 | – |
| Accounts Receivable, Allowance for Credit Loss, Writeoff | – | – | – | $0 | $0 | – |
| Accretion (Amortization) of Discounts and Premiums, Investments | $96K | $367K | -73.8% | $2.03M | $4.36M | -53.3% |
| Accrued Liabilities, Current | $210M | $65.7M | +220.2% | $78.5M | $53M | +48.1% |
| Accrued Marketing Costs, Current | $26M | $14M | +85.2% | $16.7M | $21.8M | -23.3% |
| Accrued Professional Fees, Current | $32.3M | $12.2M | +164.2% | $9.86M | $8.46M | +16.5% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $71.2M | $36.6M | +94.2% | $52.6M | $24.5M | +114.7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$46M | $822K | -5,700.6% | $2.29M | -$324K | +808.0% |
| Additional Paid in Capital, Common Stock | $662M | $712M | -7.0% | $652M | $719M | -9.3% |
| Amortization of Debt Issuance Costs and Discounts | $1.96M | $1.05M | +86.7% | $4.53M | $0 | – |
| Amortization of Intangible Assets | $18.7M | $2.8M | +567.9% | $23.7M | $3.8M | +523.7% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $44.4M | $36.7M | +21.0% | $139M | $94.6M | +46.7% |
| Assets | $3.63B | $1.88B | +93.3% | $2.15B | $708M | +204.5% |
| Assets, Current | $1.38B | $1.36B | +2.1% | $768M | $396M | +93.9% |
| Assets, Fair Value Disclosure | $440M | – | – | $822M | $145M | +465.9% |
| Business Combination, Contingent Consideration, Liability, Current | $3.65M2025-12-31 | $0 | – | $3.65M | $0 | – |
| Capital Expenditures Incurred but Not yet Paid | $7.84M | $5.94M | +32.1% | $25.2M | $7.78M | +224.4% |
| Cash and Cash Equivalents, at Carrying Value | $610M | $1.12B | -45.8% | $229M | $221M | +3.6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $610M | $1.12B | -45.8% | $229M | $221M | +3.2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $388M | $850M | -54.4% | $7.18M | $124M | -94.2% |
| Common Stock, Value, Issued | $23K | $23K | 0.0% | $23K | $22K | +4.5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$128M | $43.5M | -394.1% | $131M | $126M | +4.1% |
| Contract with Customer, Liability, Current | $141M | $98.4M | +43.7% | $127M | $75.3M | +68.9% |
| Convertible Debt, Noncurrent | $1.37B | $969M | +40.8% | $973M | $0 | – |
| Cost of Revenue | $272M | $129M | +111.8% | $614M | $303M | +102.5% |
| Current Federal Tax Expense (Benefit) | – | – | – | -$34K | $1.64M | -102.1% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $5.63M | $0 | – |
| Current Income Tax Expense (Benefit) | – | – | – | $8.52M | $7.32M | +16.4% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $2.93M | $5.68M | -48.5% |
| Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | $0 | -$384K | +100.0% | – | – | – |
| Debt Securities, Available-for-sale | $284M2025-09-30 | $88.6M | +220.7% | $79.7M2024-12-31 | $124M | -35.9% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $194K2025-09-30 | $247K | -21.5% | $124K2024-12-31 | $43K | +188.4% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $19K2025-09-30 | $0 | – | $1K2024-12-31 | $15K | -93.3% |
| Debt Securities, Available-for-sale, Amortized Cost | $284M2025-09-30 | $88.3M | +221.4% | $79.5M2024-12-31 | $124M | -36.0% |
| Debt Securities, Available-for-sale, Amortized Cost, Current | $232M | – | – | $348M | $79.5M | +338.0% |
| Debt Securities, Available-for-sale, Amortized Cost, Noncurrent | $350M2025-12-31 | – | – | $350M | – | – |
| Debt Securities, Available-for-sale, Current | $231M | $20M | +1,054.3% | $349M | $79.7M | +337.9% |
| Debt Securities, Available-for-sale, Noncurrent | $0 | – | – | $351M | $0 | – |
| Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain | $605K2025-09-30 | – | – | – | – | – |
| Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | $130K2025-09-30 | – | – | – | – | – |
| Debt Securities, Held-to-maturity, Fair Value | $438M2025-09-30 | – | – | – | – | – |
| DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss | $438M2025-09-30 | – | – | – | – | – |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$4.59M | -$43.3M | +89.4% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$6.21M | $0 | – |
| Deferred Income Tax Assets, Net | $112M | $84.2M | +32.5% | $82.7M | $61.6M | +34.3% |
| Deferred Income Tax Expense (Benefit) | -$9.36M | -$9.46M | +1.0% | -$13M | -$61.6M | +79.0% |
| Deferred Income Tax Liabilities, Net | $30.9M | – | – | $28.9M | $0 | – |
| Deferred Revenue | $119M2025-09-30 | – | – | $75.3M2024-12-31 | $7.7M | +877.9% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$2.16M | -$18.3M | +88.2% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $8.99M2025-12-31 | $276K | +3,155.8% | $8.99M | $276K | +3,155.8% |
| Deferred Tax Assets, Gross | $147M2025-12-31 | $77.1M | +90.1% | $147M | $77.1M | +90.1% |
| Deferred Tax Assets, Inventory | $5.84M2025-12-31 | $5.87M | -0.5% | $5.84M | $5.87M | -0.5% |
| Deferred Tax Assets, Net | $53.9M2025-12-31 | $61.6M | -12.6% | $53.9M | $61.6M | -12.6% |
| Deferred Tax Assets, Net of Valuation Allowance | $143M2025-12-31 | $74.6M | +91.2% | $143M | $74.6M | +91.2% |
| Deferred Tax Assets, Operating Loss Carryforwards | $19.3M2025-12-31 | $21M | -8.4% | $19.3M | $21M | -8.4% |
| Deferred Tax Assets, Operating Loss Carryforwards, Domestic | $26.3M2025-12-31 | $60.8M | -56.7% | $26.3M | $60.8M | -56.7% |
| Deferred Tax Assets, Operating Loss Carryforwards, Foreign | $31.4M2025-12-31 | $9.9M | +217.2% | $31.4M | $9.9M | +217.2% |
| Deferred Tax Assets, Operating Loss Carryforwards, State and Local | $83.7M2025-12-31 | $97.2M | -13.9% | $83.7M | $97.2M | -13.9% |
Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02